Short Interest in Indivior PLC (NASDAQ:INDV) Drops By 14.1%

Indivior PLC (NASDAQ:INDV) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,220,000 shares, a decline of 14.1% from the January 31st total of 1,420,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 1.0 days. Currently, 1.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on INDV shares. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock.

Indivior Stock Up 5.8 %

NASDAQ:INDV opened at $10.10 on Wednesday. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $22.53. The company has a market cap of $1.39 billion, a P/E ratio of -28.86 and a beta of 0.73. The firm’s 50 day moving average is $11.06 and its two-hundred day moving average is $10.63.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The firm had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $262.35 million. Research analysts forecast that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indivior

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Indivior in the 4th quarter worth approximately $359,000. Stifel Financial Corp purchased a new position in shares of Indivior in the third quarter valued at $100,000. AlphaCentric Advisors LLC acquired a new stake in Indivior during the 3rd quarter valued at $2,364,000. Clark Estates Inc. NY purchased a new stake in Indivior during the 3rd quarter worth approximately $2,477,000. Finally, Valence8 US LP acquired a new stake in Indivior during the third quarter valued at approximately $564,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.